Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2a, Open Label Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of EP-104IAR in Adults With Eosinophilic Esophagitis (RESOLVE)

Next Previous
Trial Profile

A Phase 1b/2a, Open Label Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of EP-104IAR in Adults With Eosinophilic Esophagitis (RESOLVE)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluticasone propionate (Primary)
  • Indications Eosinophilic oesophagitis
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms RESOLVE
  • Sponsors Eupraxia Pharmaceuticals

Most Recent Events

  • 08 Jul 2025 According to an Eupraxia Pharmaceuticals media release, company during the Phase 2b portion of the RESOLVE study, company will continue to report additional data from patients that were entered into the open label Phase 2a study, with further data from cohorts 5 - 8 available in early September and November of 2025.
  • 08 Jul 2025 According to an Eupraxia Pharmaceuticals media release, company plans to enroll a minimum of 60 patients in the Phase 2b portion of the RESOLVE study in up to 25 sites globally and Topline data from the Phase 2b portion of the RESOLVE study are expected by Q3 2026.
  • 08 Jul 2025 According to an Eupraxia Pharmaceuticals media release, company dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top